Accumulation of CD28null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients

Mia J Coleman; Kourtney M Zimmerly; Xuexian O Yang

doi:10.3390/biom11101425

Accumulation of CD28^null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients

Biomolecules. 2021 Sep 29;11(10):1425. doi: 10.3390/biom11101425.

Authors

Mia J Coleman^{1

2}, Kourtney M Zimmerly¹, Xuexian O Yang¹

Affiliations

¹ Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
² Class of 2023, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.

Abstract

Coronavirus disease 2019 (COVID-19), a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes infectious disease, and manifests in a wide range of symptoms from asymptomatic to severe illness and even death. Severity of infection is related to many risk factors, including aging and an array of underlying conditions, such as diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and cancer. It remains poorly understood how these conditions influence the severity of COVID-19. Expansion of the CD28^null senescent T-cell populations, a common phenomenon in aging and several chronic inflammatory conditions, is associated with higher morbidity and mortality rates in COVID-19. Here, we summarize the potential mechanisms whereby CD28^null cells drive adverse outcomes in disease and predispose patients to devastating COVID-19, and discuss possible treatments for individuals with high counts of CD28^null senescent T-cells.

Keywords: CD28null T-cells; COVID-19; cytotoxicity; immune decline; inflammation; senescence.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

CD28 Antigens / immunology*
COVID-19 / immunology*
Humans
T-Lymphocytes / immunology*

Substances

CD28 Antigens

Abstract

Publication types

MeSH terms

Substances

Grants and funding